Kercheville Advisors LLC Takes Position in AbbVie Inc. (NYSE:ABBV)

Kercheville Advisors LLC bought a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,221 shares of the company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AMF Tjanstepension AB acquired a new stake in shares of AbbVie during the 3rd quarter valued at approximately $8,777,000. Czech National Bank increased its position in AbbVie by 6.9% in the third quarter. Czech National Bank now owns 359,823 shares of the company’s stock worth $71,058,000 after buying an additional 23,320 shares during the period. City Holding Co. increased its position in AbbVie by 0.3% in the third quarter. City Holding Co. now owns 40,607 shares of the company’s stock worth $8,019,000 after buying an additional 125 shares during the period. Talbot Financial LLC increased its position in AbbVie by 1.5% in the third quarter. Talbot Financial LLC now owns 92,006 shares of the company’s stock worth $18,169,000 after buying an additional 1,344 shares during the period. Finally, Marquette Asset Management LLC acquired a new stake in AbbVie in the third quarter worth $39,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.25% of the company’s stock.

AbbVie Trading Up 0.9 %

Shares of NYSE ABBV opened at $191.74 on Thursday. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The firm has a market capitalization of $338.82 billion, a PE ratio of 79.89, a PEG ratio of 1.84 and a beta of 0.58. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The business has a 50-day moving average price of $177.01 and a two-hundred day moving average price of $185.38.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period last year, the business earned $2.79 EPS. As a group, analysts predict that AbbVie Inc. will post 12.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Daiwa Capital Markets lowered AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price on the stock. in a research report on Thursday, December 5th. Leerink Partners raised AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price on the stock in a research report on Friday, November 22nd. Argus raised AbbVie from a “hold” rating to a “buy” rating in a report on Monday, November 4th. Raymond James reissued an “outperform” rating and set a $220.00 price target (up from $218.00) on shares of AbbVie in a report on Monday. Finally, Morgan Stanley raised their price target on AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a report on Monday. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.